Search results
Results from the WOW.Com Content Network
[23] [24] The vaccine technology, for antigen production and use, is given patent-free to manufacturers, although Baylor College receives a fee. [ 17 ] [ 25 ] [ 26 ] The evaluation of adjuvant components for use in a RBD based vaccine was partially enabled by NIH funding [ 27 ] along with prior funding to support development of the CpG adjvuant ...
In the UK, 15,121 health care workers from 104 hospitals who had tested negative for antibodies prior to the study, were followed by RT-PCR tests twice a week from 7 December 2020 to 5 February 2021, a study compared the positive results for the 90.7% vaccinated share of their cohort with the 9.3% unvaccinated share, and found that the Pfizer ...
Pan-coronavirus vaccine candidates include variant-proof vaccines such as SpFN, developed by the US Army. It uses a ferritin nanoparticle with prefusion-stabilized spike antigens from the Wuhan strain. Another candidate is RBD–scNP, which is a sortase A-conjugated ferritin nanoparticle with receptor-binding domain (RBD) antigens.
According to the CDC, only 22.6% of adults reported having received an updated 2023-24 COVID-19 vaccine since September 2023. Data also shows that vaccination coverage increased by age and was ...
On January 6, the Centers for Disease Control and Prevention (CDC) announced that it had found at least 52 confirmed cases of the more contagious SARS-CoV-2 variant: 26 in California, 22 in Florida, two in Colorado, and one each in Georgia and New York.
As the U.S. nears peak respiratory virus season, these highly contagious omicron subvariants are fueling a rise in infections across the country. The HV.1 variant has been circulating in the U.S ...
The XEC variant has become the second-most prevalent strain in the country, representing more than 1 in 10 cases, according to data from the Centers for Disease Control and Prevention (CDC). (It ...
In Phase II results published in The Lancet, on the two-dose schedule, seroconversion rates of neutralizing antibodies after the second dose were 76% (114 of 150 participants) in a 25 μg group and 72% (108 of 150) in a 50 μg group. On the three-dose schedule, seroconversion rate of neutralizing antibodies after the third dose were 97% (143 of ...